Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Tempus AI's $100 Breakout — Billionaire Cliff Asness Reaps 60% Windfall

Author: Surbhi Jain | October 09, 2025 08:24am

Tempus AI Inc (NASDAQ:TEM) has become one of 2025's most dramatic comeback stories. The stock soared past $100 this week, marking a new 52-week high and sending the market buzzing about the AI-powered cancer diagnostics company's growth prospects. Investors are taking note as the stock climbs amid recent FDA clearances and a government push for AI solutions in pediatric cancer.

  • Track TEM stock here.

FDA Wins Fuel Momentum

The latest catalyst came after Tempus secured FDA clearance for its Tempus xR IVD device in late September, a breakthrough RNA sequencing tool designed to tailor therapies for cancer patients. The company's expanding portfolio of AI-powered diagnostic tools has positioned it as a leader in the AI healthcare sector.

Adding to the momentum, a recent executive order from President Donald Trump promoting AI-based solutions for pediatric cancer sent fresh optimism through the healthcare AI space.

Read Also: Cathie Wood Dumps $5.2 Million Worth of This AI Stock, Here’s What Ark Bought Instead

Billionaire Investor Bets Pay Off

Billionaire Cliff Asness of AQR Capital Management made a timely entrance into Tempus AI earlier this year, disclosing a new $54 million stake of roughly 850,000 shares at an average price of $55.89 in the second quarter of 2025. With shares now trading near $102, that stake is already up more than 60%. Asness' position in Tempus AI has already gained over $39 million, highlighting the impact of AI-focused innovation on Wall Street portfolios.

Why It Matters

Tempus AI's stock momentum underscores a broader theme: investors are betting on companies that combine AI innovation with tangible clinical applications.

FDA clearances, government backing, and successful billionaire-backed trades are fueling excitement, making TEM a stock to watch for those looking to capitalize on AI-driven healthcare growth.

Read Next:

Photo: Piotr Swat / Shutterstock

Posted In: TEM

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist